Loading…
Protagonist Therapeutics, Inc. is projected to rise to $182.60 by 2027, a +32% move from its current price of $138.64. PTGX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $135.27 | $138.69 | $142.18 | +0.03% |
| Aug 2 | $133.93 | $138.73 | $143.71 | +0.06% |
| Aug 3 | $132.91 | $138.78 | $144.90 | +0.10% |
| Aug 4 | $132.07 | $138.82 | $145.91 | +0.13% |
| Aug 5 | $131.34 | $138.87 | $146.82 | +0.16% |
| Aug 6 | $130.68 | $138.91 | $147.65 | +0.20% |
| Aug 7 | $130.09 | $138.96 | $148.43 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $130.09 | $138.96 | $148.43 | +0.23% |
| Week 2 | $126.87 | $139.27 | $152.88 | +0.46% |
| Week 3 | $124.52 | $139.59 | $156.48 | +0.68% |
| Week 4 | $122.62 | $139.91 | $159.63 | +0.91% |
| Week 5 | $121.00 | $140.22 | $162.50 | +1.14% |
| Week 6 | $119.58 | $140.54 | $165.18 | +1.37% |
| Week 7 | $118.31 | $140.86 | $167.71 | +1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. (PTGX) is a Healthcare company with a current price of $140.85 per share and a market capitalization of $9.06B. It ranks 984 by market cap among listed companies.
The stock’s near-term outlook shows an even risk profile in 2026, with a 2026 avg price of $140.85 but a range from $79.73 to $196.66 and a neutral sentiment, before stronger upside emerges in subsequent years.
A major floor 32.8% below — a decisive break under it would weaken the trend.
The nearest floor, 19.6% below — buyers have tended to step in here.
Price is pressing into resistance (1.6% away) — a breakout level to watch.
A major ceiling 15.3% above — clearing it would confirm fresh momentum.
Key PTGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PTGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $136.03 | Buy | $136.27 | Buy |
| MA 10 | $136.45 | Buy | $135.64 | Buy |
| MA 20 | $135.31 | Buy | $132.79 | Buy |
| MA 50 | $118.79 | Buy | $122.84 | Buy |
| MA 100 | $109.87 | Buy | $112.26 | Buy |
| MA 200 | $97.02 | Buy | $98.42 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.64 | Neutral |
| Stoch RSI (14) | 41.58 | Neutral |
| CCI (20) | 80.64 | Neutral |
| Williams %R (14) | -20.60 | Info |
| MACD (12,26,9) | -0.93 | Sell |
| ROC (12) | 5.61 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 79.40 | Neutral |
| TRIX (15) | 0.68 | Buy |
| Awesome (5,34) | 8.29 | Buy |
| Ultimate (7,14,28) | 55.10 | Neutral |
| Momentum (10) | 6.62 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 135.74 | Buy |
| ADX (14) | 27.01 | Buy |
| ATR (14) | 3.04 | Info |
Technically, the 30-day picture is bullish with RSI(14) at 80, indicating elevated momentum. The 50-day simple moving average stands at $106.99 and the 200-day simple moving average at $91.14, creating a supportive base near $93.23 and a resistance at $140.85. The stock has traded within a 30-day range of $118.80 to $166.99, reflecting a broad exploratory window for near-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $79.73 | $138.64 | $187.49 | 0% | Neutral | |
| $146.77 | $182.60 | $239.46 | +32% | Bullish | |
| $169.74 | $216.63 | $294.12 | +56% | Bullish | |
| $197.08 | $256.88 | $358.33 | +85% | Bullish | |
| $268.99 | $357.14 | $509.66 | +158% | Bullish | |
| $310.25 | $418.90 | $609.79 | +202% | Bullish | |
| $333.19 | $456.93 | $677.11 | +230% | Bullish | |
| $394.30 | $548.69 | $826.34 | +296% | Bullish | |
| $409.01 | $577.08 | $882.10 | +316% | Bullish | |
| $435.43 | $622.53 | $964.81 | +349% | Bullish | |
| $743.08 | $1,127.62 | $1,851.93 | +713% | Bullish | |
| $1,627.70 | $2,733.76 | $4,886.98 | +18.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $79.73 | $138.64 | $161.58 | +0.00% |
| August 2026 | $117.76 | $137.96 | $165.19 | -0.49% |
| September 2026 | $120.98 | $142.81 | $173.11 | +3.52% |
| October 2026 | $125.55 | $149.11 | $182.51 | +4.41% |
| November 2026 | $125.48 | $149.78 | $184.77 | +0.45% |
| December 2026 | $125.85 | $150.91 | $187.49 | +0.75% |
Click any year to see its month-by-month PTGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PTGX price prediction for 2026 points to an average of $138.64 (low $79.73, high $187.49) — a potential gain of 0% on today's $138.64. Price action looks broadly range-bound.
In 2027, PTGX is projected to trade between $146.77 and $239.46, averaging $182.60 — a potential gain of +32% from today's $138.64. That is up +32% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Protagonist Therapeutics, Inc.'s 2028 outlook centres on $216.63, within a $169.74 to $294.12 range. That is up +19% on the projected 2027 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2029, PTGX could reach as high as $358.33, with a base case around $256.88 and support toward $197.08 — roughly +85% from $138.64. Buyers look set to stay in control over this stretch.
Expect PTGX to range from $268.99 to $509.66 through 2030. The $357.14 average target implies a +158% move from current prices. That is up +39% on the projected 2029 average. Momentum favours further upside here.
The PTGX price prediction for 2031 points to an average of $418.90 (low $310.25, high $609.79) — a potential gain of +202% on today's $138.64. Buyers look set to stay in control over this stretch.
In 2032, PTGX is projected to trade between $333.19 and $677.11, averaging $456.93 — a potential gain of +230% from today's $138.64. That is up +9% on the projected 2031 average. Momentum favours further upside here.
Protagonist Therapeutics, Inc.'s 2033 outlook centres on $548.69, within a $394.30 to $826.34 range. That is up +20% on the projected 2032 average. That marks a +296% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, PTGX could reach as high as $882.10, with a base case around $577.08 and support toward $409.01 — roughly +316% from $138.64. Momentum favours further upside here.
Expect PTGX to range from $435.43 to $964.81 through 2035. The $622.53 average target implies a +349% move from current prices. That is up +8% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The PTGX price prediction for 2040 points to an average of $1,127.62 (low $743.08, high $1,851.93) — a potential gain of +713% on today's $138.64. Momentum favours further upside here.
In 2050, PTGX is projected to trade between $1,627.70 and $4,886.98, averaging $2,733.76 — a potential gain of +18.7x from today's $138.64. That is up +142% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PTGX today (≈ 7.212926 PTGX) could be worth
$19,718.39
+$18,718.39 (+1872%) by 2050 · US Dollar
Based on the average projected PTGX price of $2,733.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PTGXwould be worth at today's price.
$1,000 invested in PTGX on Jul 30, 2025 (≈ 18.308312 PTGX) would be worth
$2,538.26
+$1,538.26 (+153.8%) today · 2.54× · US Dollar
Based on a PTGX entry price of $54.62 vs. today's $138.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $135.43 | $1,023.7 | +2.4% |
| 1 month ago | $122.58 | $1,131.02 | +13.1% |
| 3 months ago | $98.37 | $1,409.37 | +40.9% |
| 6 months ago | $81.8 | $1,694.87 | +69.5% |
| 1 year ago | $54.62 | $2,538.26 | +153.8% |
| All time (5.0y) ago | $49.08 | $2,824.78 | +182.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PTGX forecast.
Our base-case forecast reaches $280.00 around 2030.
Implied market cap at $280.00: $18.01B
The multi-year forecast shows a clear upside path with rising averages and high-end targets. For 2030 the model gives an average price of $362.62 and a max of $521.70 with a 157.4% ROI and bullish sentiment, illustrating substantial longer-term upside. Earlier years like 2027–2029 show positive momentum, culminating in a 2040 average of $1,077.01 with a 664.6% ROI and a 2050 average of $2,735.49 with a 1,842.1% ROI, all tagged as bullish.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $362.62, a minimum of $271.27, and a maximum of $521.70 with an ROI of 157.4% and a bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with substantial upside by 2030 and later years; the near term (2026) is neutral with an average of $140.85. These are estimates, not guarantees.
Yes. The 2040 forecast lists an average of $1,077.01 and a maximum of $1,788.80, with a bullish outlook and a 664.6% ROI.
The 2050 forecast lists an average of $2,735.49 and a maximum of $4,954.57, with a bullish sentiment. The maximum is below $5,000, so a 5,000-level is not projected.
The current price is $140.85 and the market capitalization is $9.06B.
Protagonist Therapeutics, Inc. Community Discussion
0Share your Protagonist Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.